Another Bet on Psychedelic Drugs: Atai Raises $125 Million
by myeboga
Text size Dreamstime With investors taking psychedelic drugs seriously as potential treatments for intractable cases of depression, addiction, or post-traumatic disorder, the stock plays are flying. Since the September initial offering of Compass Pathways ’ depositary shares, the developer of an experimental psilocybin treatment has seen its stock (ticker: CMPS) double, to a recent $35.73. …
by myeboga 
Psychedelics-Drug Startup Raises $24 Million Ahead of IPO
by myeboga
Ibogaine comes from iboga, a West African plant whose yellowish root bark induces powerful psychedelic experiences. Hallmarks of ibogaine trips … Source link
by myeboga